Schrödinger Announces Strategic Priorities for 2025, Advances Clinical Programs

Schrödinger, Inc. (Nasdaq: SDGR) has announced its strategic priorities for 2025, building on progress made in 2024 across its software platform and drug discovery programs. The company is poised to present initial Phase 1 data from three proprietary oncology programs while expanding collaborations and driving growth in its computational technology.

Advancing Clinical Programs

Schrödinger is actively advancing three clinical-stage oncology programs and expects to present initial data from Phase 1 studies in 2025:

• SGR-1505: A MALT1 inhibitor being evaluated in patients with relapsed/refractory B-cell lymphomas. Initial Phase 1 data is expected in the first half of 2025.
• SGR-2921: A CDC7 inhibitor being studied in patients with relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). Initial Phase 1 data is anticipated in the second half of 2025. The FDA has granted Fast Track Designation for SGR-2921 for the treatment of relapsed/refractory AML.
• SGR-3515: A Wee1/Myt1 inhibitor in Phase 1 development for patients with advanced solid tumors. Initial Phase 1 data is expected in the second half of 2025. Preclinical data on SGR-3515 was presented at the EORTC-NCI-AACR Symposium.

Expanded Collaborations

Schrödinger has expanded its research collaboration with Otsuka Pharmaceutical (搜索)搜索该词条 Co., Ltd., adding another undisclosed target. The terms of the expanded collaboration are consistent with the previously announced agreement. Furthermore, the research collaboration with Novartis查看公司主页 has received regulatory clearance, with Schrödinger expecting to receive a $150 million upfront payment in the first quarter of 2025. The Novartis collaboration includes potential milestone payments and royalties up to $2.3 billion.

Progress in Co-Founded Companies

Several companies co-founded by Schrödinger have achieved significant milestones:

• Ajax Therapeutics: Initiated a Phase 1 clinical trial for its lead program, AJ1-11095, and completed a Series C financing.
• Morphic Holding, Inc.: Was acquired by Lilly for approximately $3.2 billion, resulting in approximately $48 million in cash for Schrödinger, with Schrödinger remaining entitled to low single-digit royalties on selected pipeline programs, including MORF-057, its orally administered α4β7 inhibitor.
• Nimbus Therapeutics: Presented updated Phase 1/2 data for NDI-101150, its HPK1 inhibitor, at the Society for Immunotherapy of Cancer Annual Meeting.
• Structure Therapeutics: Presented Phase 1b/2a data for GSBR-1290, its oral GLP-1 agonist, in obesity and diabetes at the Annual Meeting of the America Diabetes Association and announced the selection of ACC-2671, its novel oral small molecule amylin receptor agonist for further development in obesity.

Strategic Priorities for 2025

Schrödinger has outlined the following strategic priorities for 2025:

1. Drive increased customer adoption of its computational technology and enterprise informatics platform.
2. Advance the science underlying the platform, including progressing the predictive toxicology initiative, which is being funded by $19.5 million in grants from the Bill & Melinda Gates Foundation.
3. Present initial data from the Phase 1 studies of SGR-1505, SGR-2921 and SGR-3515.
4. Advance proprietary and collaborative discovery portfolio.

"We are very proud of our accomplishments in 2024... We have a very important year ahead of us and are committed to driving growth in our software business, advancing our collaborative pipeline and reporting initial Phase 1 data from our three lead proprietary therapeutic programs," stated Ramy Farid, Ph.D., chief executive officer at Schrödinger.